Literature DB >> 3401215

Renal glomerular proteoglycans. An investigation of their synthesis in vivo using a technique for fixation in situ.

L A Beavan1, M Davies, R M Mason.   

Abstract

Newly synthesized rat glomerular [35S]proteoglycans were labelled in vivo after injecting Na2[35S]SO4 intraperitoneally. At the end of the labelling period (7 h) the kidneys were perfused in situ with 0.01% (w/v) cetylpyridinium chloride. This fixed proteoglycans in the tissue and increased their recovery 2-3-fold during subsequent isolation of glomeruli from the renal cortex. The glomeruli were fractionated by a modified osmotic lysis and detergent extraction procedure [Meezan, Brendel, Hjelle & Carlson (1978) in The Biology and Chemistry of Basement Membranes (Kefalides, N.A., ed.), Academic Press, New York; Kanwar & Farquhar (1979) Proc. Natl. Acad. Sci. U.S.A. 76, 4493-4497] to obtain a basement membrane preparation. The proteoglycans released at each stage of the procedure were characterized using DEAE-Sephacel ion-exchange chromatography, chondroitinase ABC and HNO2 digestion and Sepharose CL-4B gel-permeation chromatography. About 85% of the [35S]proteoglycans synthesized were of the heparan sulphate variety, the remainder being chondroitin sulphate proteoglycans. Three sizes of heparan sulphate proteoglycans were identified. The largest (HS1, Kav. 0.47) accounts for 44% of the total extractable heparan sulphates. About one third of HS1 were extracted from the glomerular basement-membrane fraction with 8 M-urea and 4 M-guanidine hydrochloride but the remainder were released from the glomerulus during preparation of the fraction. The two smaller molecules (HS2, Kav. 0.56 and HS3, Kav. 0.68) accounted for 27% and 28% of the extractable heparan sulphate respectively and were not associated with the basement membrane fraction. HS1, HS2 and HS3 were also isolated from non-fixed glomeruli labelled in vivo but with much lower recovery. In glomeruli labelled in vitro, heparan sulphate accounted for only 35% of the proteoglycans, the remainder being of the chondroitin sulphate type. Proteoglycans similar to HS1, HS2 and HS3 were present in glomeruli labelled in vitro but, in addition, a large, highly charged heparan sulphate (HS1a) was extracted from the glomerular basement-membrane fraction of these glomeruli. It accounted for 6% of the total heparan sulphate.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3401215      PMCID: PMC1149018          DOI: 10.1042/bj2510411

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  28 in total

1.  Isotopic procedures in the structural analysis of heparin.

Authors:  J E Shively; H E Conrad
Journal:  Fed Proc       Date:  1977-01

2.  Localization of the nephrotoxic antigen within the isolated renal glomerulus.

Authors:  C A KRAKOWER; S A GREENSPON
Journal:  AMA Arch Pathol       Date:  1951-06

3.  Formation of anhydrosugars in the chemical depolymerization of heparin.

Authors:  J E Shively; H E Conrad
Journal:  Biochemistry       Date:  1976-09-07       Impact factor: 3.162

4.  Structures and immunochemical properties of oligosaccharides isolated from pig submaxillary mucins.

Authors:  D M Carlson
Journal:  J Biol Chem       Date:  1968-02-10       Impact factor: 5.157

5.  Non-collagen protein and proteoglycan in renal glomerular basement membrane.

Authors:  M P Cohen; V Y Wu; M L Surma
Journal:  Biochim Biophys Acta       Date:  1981-12-18

6.  Nearest neighbor analysis of heparin: identification and quantitation of the products formed by selective depolymerization procedures.

Authors:  J E Shively; H E Conrad
Journal:  Biochemistry       Date:  1976-09-07       Impact factor: 3.162

7.  Isolation of glycosaminoglycans (heparan sulfate) from glomerular basement membranes.

Authors:  Y S Kanwar; M G Farquhar
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

8.  Sulfated and nonsulfated glycosaminoglycans and glycopeptides are synthesized by kidney in vivo and incorporated into glomerular basement membranes.

Authors:  M C Lemkin; M G Farquhar
Journal:  Proc Natl Acad Sci U S A       Date:  1981-03       Impact factor: 11.205

9.  Glycosaminoglycan synthesis by glomeruli in vivo and in vitro.

Authors:  D M Brown; A F Michael; T R Oegema
Journal:  Biochim Biophys Acta       Date:  1981-04-17

10.  Partial characterization of newly synthesized proteoglycans isolated from the glomerular basement membrane.

Authors:  Y S Kanwar; V C Hascall; M G Farquhar
Journal:  J Cell Biol       Date:  1981-08       Impact factor: 10.539

View more
  6 in total

1.  A steady-state labelling approach to the measurement of proteoglycan turnover in vivo and its application to glomerular proteoglycans.

Authors:  E L Akuffo; J R Hunt; J Moss; D Woodrow; M Davies; R M Mason
Journal:  Biochem J       Date:  1996-11-15       Impact factor: 3.857

2.  Urine proteome analysis in murine nephrotoxic serum nephritis.

Authors:  Scott E Wenderfer; William P Dubinsky; Mayra Hernandez-Sanabria; Michael C Braun
Journal:  Am J Nephrol       Date:  2009-09-24       Impact factor: 3.754

3.  Selective proteinuria in diabetic nephropathy in the rat is associated with a relative decrease in glomerular basement membrane heparan sulphate.

Authors:  J van den Born; A A van Kraats; M A Bakker; K J Assmann; L P van den Heuvel; J H Veerkamp; J H Berden
Journal:  Diabetologia       Date:  1995-02       Impact factor: 10.122

4.  Anionic charge concentration of rat kidney glomeruli and glomerular basement membrane.

Authors:  W D Comper; A S Lee; M Tay; Y Adal
Journal:  Biochem J       Date:  1993-02-01       Impact factor: 3.857

5.  Effect of lipoid nephrosis cytokine on glomerular sulfated compounds and albuminuria.

Authors:  E H Garin
Journal:  Pediatr Nephrol       Date:  1995-10       Impact factor: 3.714

6.  The effect of lymphocytes from renal transplant patients on glomerular basement membrane sulfate uptake.

Authors:  E H Garin; S E Self
Journal:  Pediatr Nephrol       Date:  1995-06       Impact factor: 3.714

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.